Global Neuromuscular blockade Drugs Market, By Type (Depolarizing, Non-depolarizing, Others), Drugs Succinylcholine, Cisatracurium, Mivacurium, Doxacurium, Rocuronium, Atracurium, Pancuronium, Vecuronium, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
Neuromuscular Blockade Drugs Market Analysis and Size
Growing elderly populations worldwide who are more vulnerable to musculoskeletal disorders are the main factor driving the market growth. Neuromuscular blockades are powerful drugs, though these can have severe side effects such as heart failure, sedation, and paralysis. In many patients, sedation is witnessed as the common adverse effect. Consequently, physicians generally advise against driving or operating heavy machinery after neuromuscular blockade administration.
Data Bridge Market Research analyses a growth rate in the global neuromuscular blockade drugs market in the forecast period 2022-2029. The global neuromuscular blockade drug market's expected CAGR tends to be around 4.50% in the mentioned forecast period. The market was valued at USD 5 billion in 2022, and it would grow to USD 7.11 billion by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Neuromuscular Blockade Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Depolarizing, Non-depolarizing, Others), Drugs (Succinylcholine, Cisatracurium, Mivacurium, Doxacurium, Rocuronium, Atracurium, Pancuronium, Vecuronium, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland), Endo International plc (Ireland), Intas Pharmaceuticals Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Neuromuscular blocking agents or medications are the type of muscle relaxants that are widely used to prevent muscle contraction during surgery. They are structurally similar to acetylcholine and bring muscle relaxation by post-synaptic binding to acetylcholine receptors. Furthermore, when artificial ventilation is available, such agents should be used instead of anesthesia.
Global Neuromuscular Blockade Drugs Market Dynamics
Drivers
- Growing Prevalence of Musculoskeletal Issues
The rising prevalence of musculoskeletal problems and increasing customer awareness of their treatment and management are raising the market's growth. Structurally distinct medications are the recent technologically improved neuromuscular blockades used to relax muscle spasms, discomfort, and hyperreflexia. This boosts the growth of the market.
- Major Developments by the Market Players
There are numerous developments done by major market players that are boosting the growth of the market. For instance, in September 2019, Ipsen Biopharmaceuticals received U.S. FDA approval for expanded use of Dysport for injection to treat children two years of age and older having upper limb spasticity, excluding spasticity caused by cerebral palsy. Thus, this leads to market expansion.
Opportunities
- Growing Elderly Population
Life expectancy is rising around the world, which has led to an increase in the aging population. This trend positively impacts the market by increasing the prevalence of the disease and creating per capita demand for its remedies. Thus, this set population demands high use of demyelinating disease therapeutics and, in return, creates more opportunities for market growth.
- Growing Prevalence of Lower Back Pain
According to the records of the World Health Organization (WHO), the non-specific burden of lower back pain has increased significantly globally, which is projected at 60–70% in industrialized countries, whereas one-year incidence increased rate 15–45%, adult prevalence 5% per annum and mostly incidence of lower back pain has seen in above 35 age bracket people. Thus, this factor demands more drugs and, as a result, is increasing the market's growth.
Restraints/Challenges
- Adverse Side-Effects of Neuromuscular blockades
There are severe side effects that are linked with neuromuscular blockades, such as dry mouth, tiredness, dizziness, and depression which restrict the market growth.
- High Investment and Strict Regulatory Norms
The growth of the neuromuscular blockade drug market is limited by factors such as strict regulatory requirements and the risks related to neuromuscular blockades. The use, separation, and development of raw materials for the development of pharmaceutical and biopharmaceutical drugs demand professional and qualified personnel. Thus, all these factors restrict the growth of the demand for neuromuscular blockade drugs.
This global neuromuscular blockade drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neuromuscular blockade drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Neuromuscular Blockade Drugs Market
Musculoskeletal pain is observed to be a common problem in routine medical practice. Many pain sources are associated with muscles or fascia becoming damaged, which then triggers pain. Although COVID-19 primarily affects the lungs and internal organs, musculoskeletal injury from this disease was visible because of the marked elevation in creatine kinase and lactate dehydrogenase levels. Moreover, pain management during the COVID-19 pandemic demands attention because of difficulties accessing hospitals for medical services such as physical therapy and rehabilitation. Thus, COVID-19 greatly impacted the global neuromuscular blockade drugs market.
Global Neuromuscular Blockade Drugs Market Scope
The global neuromuscular blockade drugs market is segmented on the basis of type, drugs, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Depolarizing
- Non-depolarizing
- Others
Drugs
- Succinylcholine
- Cisatracurium
- Mivacurium
- Doxacurium
- Rocuronium
- Atracurium
- Pancuronium
- Vecuronium
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Neuromuscular Blockade Drugs Market Regional Analysis/Insights
The global neuromuscular blockade drugs market is analysed and market size insights and trends are provided by type, drugs,end-user, distribution channel as referenced above.
The major countries covered in the global neuromuscular blockade drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the region's increased R&D activities on muscle relaxants and well-established healthcare infrastructure.
Asia-Pacific is dominating the market due to increased advancement in technology, and the huge development of novel molecules for the treatment of pain and spasms
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Neuromuscular Blockade Drugs Market Share Analysis
The global neuromuscular blockade drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neuromuscular blockade drugs market.
Key players operating in the global neuromuscular blockade drugs market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Actelion Pharmaceuticals Ltd (Switzerland
- Endo International plc (Ireland)
- Intas Pharmaceuticals Ltd. (India)
SKU-